Ignite Creation Date:
2024-05-05 @ 11:26 AM
Last Modification Date:
2024-10-26 @ 9:08 AM
Study NCT ID:
NCT00046735
Status:
COMPLETED
Last Update Posted:
2019-11-18
First Post:
2002-10-02
Brief Title:
Phase 1 Study OF CDC-501 in Patients With Solid Tumors
Sponsor:
Celgene
Organization:
Celgene
Study Overview
Official Title:
A Single-Center Open-Label Between-Patient Dose-Escalation Phase 1 Study of CDC-501 In Patients With Solid Tumors
Status:
COMPLETED
Status Verified Date:
2019-11
Last Known Status:
None
Delayed Posting:
No
If Stopped, Why?:
Not Stopped
Has Expanded Access:
False
If Expanded Access, NCT#:
N/A
Has Expanded Access, NCT# Status:
N/A
Acronym:
None
Brief Summary:
To identify the maximum tolerated dose MTD and safety of CDC-501 when given in a 6-week cycle in patients with solid tumors that are refractory after standard treatment
Detailed Description:
Identify the maximum tolerated dose MTD and safety of CDC-501 when given in a 6-week cycle in patients with solid tumors that are refractory after standard treatment
Study Oversight
Has Oversight DMC:
None
Is a FDA Regulated Drug?:
None
Is a FDA Regulated Device?:
None
Is an Unapproved Device?:
None
Is a PPSD?:
None
Is a US Export?:
None
Is an FDA AA801 Violation?:
None